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Abstract
Differentiation of the protozoan parasite Toxoplasma gondii into its latent bradyzoite stage is
a key event in the parasite’s life cycle. Compound 2 is an imidazopyridine that was previously
shown to inhibit the parasite lytic cycle, in part through inhibition of parasite cGMP-
dependent protein kinase. We show here that Compound 2 can also enhance parasite differ-
entiation, and we use yeast three-hybrid analysis to identify TgBRADIN/GRA24 as a parasite
protein that interacts directly or indirectly with the compound. Disruption of the TgBRADIN/
GRA24 gene leads to enhanced differentiation of the parasite, and the TgBRADIN/GRA24
knockout parasites show decreased susceptibility to the differentiation-enhancing effects of
Compound 2. This study represents the first use of yeast three-hybrid analysis to study
small-molecule mechanism of action in any pathogenic microorganism, and it identifies a
previously unrecognized inhibitor of differentiation in T. gondii. A better understanding of the
proteins and mechanisms regulating T. gondii differentiation will enable new approaches to
preventing the establishment of chronic infection in this important human pathogen.
Introduction
Apicomplexan parasites, including those that cause malaria, toxoplasmosis and cryptosporidi-
osis, have developed a variety of strategies to persist in their hosts and achieve high transmis-
sion rates. These protozoan parasites have complex life cycles that typically include a sexual
cycle in the definitive host and an asexual cycle in intermediate host(s). Some apicomplexans
can form intracellular tissue cysts during their asexual cycle. The tissue cysts contain latent but
highly infectious parasites surrounded by a cyst wall. Toxoplasma gondii, one of the most suc-
cessful of the cyst-forming parasites, infects a wide range of intermediate hosts and can be hori-
zontally transmitted between them by ingestion of tissue cysts without the need for passage
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through its definitive host [1]. The differentiation process that enables T. gondii to form tissue
cysts is therefore of central importance to its life cycle.
During the initial acute phase of infection with T. gondii, tachyzoite-stage parasites invade
and replicate rapidly, disseminating throughout the body. A strong adaptive immune response
ultimately controls the acute infection but results in establishment of the chronic phase, where-
in tachyzoites differentiate into bradyzoites and form tissue cysts, primarily in the brain and
muscle. Tissue cysts can persist for the life of the host. However, if the individual becomes im-
munosuppressed, the infection can re-activate: bradyzoites differentiate back into tachyzoites,
which replicate and disseminate, causing tissue lysis and inflammatory damage that can lead to
blindness, encephalitis and death [2,3]. The mechanisms that regulate bradyzoite development
are therefore of major clinical relevance.
Stress conditions and insults from the immune system are thought to be the natural induc-
ers of tachyzoite-to-bradyzoite differentiation in infected hosts. Differentiation can also be ex-
perimentally induced in culture by heat shock [4], nutrient starvation [5], alkaline pH [6], and
a wide variety of drugs including compounds that affect cyclic nucleotide signaling [7]. Analy-
sis of the parasite transcriptome by microarray and SAGE (serial analysis of gene expression)
has revealed large numbers of developmentally regulated genes [8–12]. Mutant parasite strains
incapable of switching to the bradyzoite stage have been used to identify positive regulators of
differentiation [10,12] and analyses of the epigenetic state of developmentally regulated genes
[13–15] have shown that histone acetyltransferases, deacetylases and methyltransferases also
affect expression of tachyzoite and bradyzoite-specific genes in vitro. These studies suggest that
differentiation is a highly regulated process in which groups of genes are turned on and off
in a specific temporal order [16]. Indeed, specific members of the ApiAP2 family of transcrip-
tion factors are emerging as key regulators of the tachyzoite-to-bradyzoite developmental
switch [17–19].
Compound 1 is a trisubstituted pyrrole initially identified in a cell-based screen designed to
discover kinase inhibitors that block the growth of coccidian parasites in vitro. Compound 1 is
a potent inhibitor of growth, attachment, invasion and motility of T. gondii (IC50 0.23–1.2 μM;
[20]), and was shown to directly inhibit parasite cGMP-dependent protein kinase (TgPKG)
[21]. In addition, Compound 1 enhances tachyzoite-to-bradyzoite differentiation, likely
through a host cell target [22].
In an effort to identify more potent inhibitors of coccidian PKG, a collection of structurally-
related compounds was screened and a second small molecule, Compound 2 (Fig. 1A), was
found to be an even more potent inhibitor of host cell invasion by T. gondii and related para-
sites (10–50nM; [23,24]). In vitro, Compound 2 was shown to be a potent inhibitor not only of
TgPKG but also of Calcium Dependent Protein Kinase 1 (TgCDPK1) and Casein Kinase 1α
(TgCK1α) [24]. The effect of Compound 2 on differentiation was not reported.
In the present study, we show that Compound 2 increases the rate of T. gondii tachyzoite-
to-bradyzoite differentiation and enhances tissue cyst formation. In the first application of
yeast three-hybrid analysis to small-molecule target identification in apicomplexan parasites,
we identify TgBRADIN/GRA24 as a parasite protein that interacts with Compound 2. We
show that TgBRADIN/GRA24 functions as an inhibitor of differentiation, and that Com-
pound 2 exerts at least part of its differentiation-enhancing effect through a pathway that
involves TgBRADIN/GRA24. These data enhance our understanding of the proteins
involved in stage conversion in T. gondii, and may ultimately contribute to the
development of new approaches to preventing tissue cyst formation and/or reactivation
in human infections.
TgBRADIN/GRA24 Inhibits the Differentiation of T. gondii
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Methods
Differentiation assays
T. gondii parasites were cultured by passaging in human foreskin fibroblast (HFF; American
Type Culture Collection [ATCC] CRL-1634) monolayers as described previously [25]. Conflu-
ent HFF monolayers in 6-well plates were infected with tachyzoites at a multiplicity of infection
of 5x105 and incubated in CO2 starvation media (Minimum Essential Medium lacking sodium
bicarbonate but containing 1% v/v fetal bovine serum (FBS), 25mMHEPES, 20U/ml Penicillin,
20μg/ml Streptomycin and 2mM L-Alanyl-L-Glutamine dipeptide) at 37°C with 0.03% CO2
for 72 hr. The coverslips were fixed in phosphate buffered saline (PBS) containing 4% v/v para-
formaldehyde for 20 min, permeabilized in PBS containing 0.25% v/v Triton X-100 for 15 min
and blocked in PBS containing 1% w/v bovine serum albumin for 1 hr. Coverslips were incu-
bated for 30 min with rabbit polyclonal anti-Toxoplasma (catalog #90700556; AbD Serotec, Ra-
leigh NC), diluted 1:2000 in blocking solution. Samples were then incubated with goat anti-
Fig 1. Compound 2 enhances differentiation. A. Structure of Compound 2. B. Immunofluorescence of a
cyst-like structure using an anti-Toxoplasma antibody (green) to detect all parasites and Dolichos biflorus
lectin (DL; red) to detect the cyst wall after 72 hr under CO2 starvation conditions. The corresponding
differential interference contrast (DIC) and merged images are also shown. Scale bar = 10μm. C. Percentage
of DL-positive vacuoles (DL+) in samples treated with either Compound 2 (3μM) or an equivalent volume of
DMSO for 72 hr under CO2 starvation conditions (mean ± SD; n = 4 for the wild-type strain and n = 6 for Δuprt
strains). The data were compared using paired Student’s t-test (**p< 0.01).
doi:10.1371/journal.pone.0120331.g001
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rabbit IgG conjugated to Alexa 488 (Invitrogen, Grand Island NY) at a 1:500 dilution together
with TRITC-conjugated Dolichos biflorus lectin (Sigma-Aldrich, St. Louis MO) at a dilution of
1:100 for 60 min. Alternatively, samples were incubated with rabbit anti-HSP30/BAG1 anti-
body (generously provided by Dr. Sergio Angel) at a dilution of 1:100 and mouse anti-IMC1
(MAb 45.36 at 0.75 μg/ml) followed by goat anti-rabbit IgG conjugated to Alexa 546 (Invitro-
gen) and goat anti-mouse IgG conjugated to Alexa 488, each at 1:500. The coverslips were im-
aged at 100X on a Nikon Eclipse TE300 epifluorescence microscope; 300–600 vacuoles were
counted blind along the transverse axis of each coverslip.
Differentiation assays in which the parasites were treated with Compound 2 post-infection
were done as described above with the modification that parasites were allowed to invade the
monolayer in Dulbecco’s Minimum Essential Medium (supplemented with 1% v/v FBS, 5mM
HEPES, 20U/ml Penicillin and 20μg/ml Streptomycin) for 1 hr at 37°C with 5% CO2. The in-
fected monolayers were washed three times with fresh medium and the medium was replaced
with CO2 starvation medium containing either Compound 2 or the equivalent amount
(0.25% v/v) of DMSO. Plates were incubated for 72 hr at 37°C with 0.03% CO2 and processed
for fluorescence microscopy as described above.
We observed that the percentage of vacuoles in an infected HFF monolayer that form cyst-
like structures under CO2 starvation conditions is dependent upon host cell passage number,
with higher levels of differentiation in older cells (data not shown). Similarly, treatment of in-
fected monolayers with 0.25% v/v DMSO (vehicle) under CO2 starvation conditions also en-
hances differentiation, explaining the differences seen in the induction level of wild-type
parasites with and without DMSO (compare Figs. 1C and 6A).
Synthesis of Compound 2 and MTX-Cmpd2.1
Compound 2 was synthesized using a modified version of a previously published procedure
([26]; see Scheme I in S1 Methods for details). The synthesis of MTX-Cmpd2.1 was achieved
in 3 main steps: (1) synthesis of the Compound 2–linker fragment (Scheme II in S1 Methods);
(2) synthesis of tbutyl-methotrexate (tBu-MTX) (Scheme III in S1 Methods) and (3) coupling
of these 2 fragments followed by tbutyl ester hydrolysis (Scheme IV in S1 Methods). An analo-
gous approach to MTX-Cmpd1.1 was also taken (Scheme V in S1 Methods).
Cloning of Compound 2 targets in the Y3H vector
The coding sequence for TgCK1α was PCR amplified from our oligo(dT)-primed cDNA li-
brary using primers P1 and P2 (S1 Table). The PCR product (1kb) was then subcloned into
pGEM-T Easy (Promega, Madison WI) following manufacturer’s instructions. The TgCK1α
insert was excised from the subcloning vector using MfeI and ligated into the EcoRI site of the
Y2H vector pJG4–5 [27]. This places the insert in frame with the B42 activation domain (AD)
encoded in pJG4–5. The orientation of the insert was verified by restriction digest.
The TgPKG coding sequence corresponding to isoform 2 (M102 to the stop) [28] was am-
plified from cDNA using primers P3 and P4 (S1 Table). The cDNA was prepared from RH
tachyzoite total RNA using Accuscript reverse transcriptase (Agilent Technologies, Santa Clara
CA) following manufacturer’s instructions. The PCR product was subcloned into pGEM-T
Easy and then cloned in pMW102 [29] at the EcoRI site.
The coding sequence for TgCDPK1 was amplified from cDNA using primers P5 and P6
(S1 Table). The sequence added to the 5’ end of the primers shares homology to sequence flank-
ing the EcoRI site in the linearized plasmid pJG4–5, and once in the yeast cell these two DNA
molecules will recombine to regenerate a circular plasmid [30]. The 1.5kb PCR fragment was
co-transformed into yeast strain V784Y along with EcoRI-linearized and dephosphorylated
TgBRADIN/GRA24 Inhibits the Differentiation of T. gondii
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pJG4–5. Yeast transformation was performed using the LiAc/ssDNA/PEGmethod [31]. Plas-
mid was isolated from yeast grown on synthetic complete media with glucose and lacking tryp-
tophan (SC +Glu-trp) to select for clones containing the recombinant plasmid. Positive clones
were confirmed by PCR. Plasmid was isolated using an adaptation of the bacterial miniprep pro-
tocol (Promega): cells were lysed by two freeze-thaw cycles, followed by incubation in 150mM
NaCl, 1% w/v SDS and 0.05% v/v Tween 20 and phenol-chloroform extraction prior to neutrali-
zation of the yeast extract.
The C-terminal portion of isoform TgBRADIN-a was amplified using primers P7 and P8
(S1 Table). The 676bp fragment was subcloned into pGEM-T Easy, digested with EcoRI and li-
gated at the EcoRI site in pJG4–5. Orientation of the insert in the final construct was confirmed
by restriction digest.
Reporter activation assays
Growth assays to test for the activation of the LEU2 reporter in yeast strain V784Y were done
both in plate and liquid culture. In-plate assays were done by spotting 1μl of yeast suspension
onto dropout plates (SC +Gal/Raff-his-trp-ura-leu) containing 2% w/v galactose and 1% w/v
raffinose in order to induce the Gal1 promoter that drives the expression of the prey/target fu-
sion protein. The plates were spread with the appropriate amount of CID dissolved in DMSO
using sterile glass beads the day prior to spotting the yeast, and kept at 21°C until ready to use.
The yeast suspension was prepared by resuspending a fixed amount of yeast with a sterile pipet
tip in 100μl of sterile double-distilled water. Plates were incubated at 30°C for 2–6 days
wrapped with parafilm. Liquid growth assays were performed by diluting the yeast from a satu-
rated overnight culture to 2x105 cells/well in a sterile flat-bottom clear 96-well plate (Becton-
Dickinson, Franklin Lakes NJ) with 150μl of the appropriate selective media containing either
CID or the equivalent amount of DMSO. The plates were wrapped with parafilm and incubat-
ed at 30°C with shaking at 80rpm. Every 24 hr the absorbance at 600nm was measured using a
pre-heated plate reader (BioTek, Winooski VT). Cell suspensions were mixed by pipetting
prior to each measurement.
To measure activation of the LacZ gene, the standard liquid β-Galactosidase assay as de-
scribed in the Yeast Protocols Handbook (PT3024–1; Clontech, Mountain View CA) was
adapted to 150μl cultures grown in 96-well plates. Briefly, saturated overnight cultures were di-
luted 1:100 in SC +Gal/Raff-his-trp-ura media in sterile flat-bottom 96-well plates and incubat-
ed at 30°C for 72 hr. Yeast cultures were collected and centrifuged at 21°C at 16000xg for 5
min. The pellets were washed once with double-distilled water and resuspended in freshly pre-
pared breaking buffer containing 1x protease inhibitor mix (P8340; Sigma-Aldrich, St. Louis
MO), 100mM Tris-HCl pH8.0, 1mMDTT and 20% v/v glycerol. Acid-washed beads were
added to each tube to fill the volume up to the meniscus and the cells were broken by 10 x 15
sec pulses of vortexing, each pulse followed by 1 min incubation on ice. The spheroblast sus-
pension was then solubilized in 0.1% w/v SDS for 10 min at 21°C. 25μl of each lysate was used
to measure total protein concentration by the standard microtiter Bradford assay (BioRad,
Hercules CA). The rest of the extract was used for the β-galactosidase assay using CPRG
(Roche, Indianapolis IN) as substrate, as described in the Yeast Protocols Handbook
(Clontech).
cDNA library generation
The Toxoplasma cDNA library was generated using mRNA from RH strain extracellular tachy-
zoites. Total RNA (762μg) was extracted from 100 T75 flasks of freshly egressed parasites using
the animal cell protocol of the RNeasy kit (QIAGEN, Valencia CA). The quality of the
TgBRADIN/GRA24 Inhibits the Differentiation of T. gondii
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extracted total RNA was assessed by chromatography with the 2100 Agilent Bioanalyzer (Agi-
lent Technologies, Santa Clara CA). RNA preparations containing more than 5% contamina-
tion of host cell-derived RNA were discarded. The mRNA was isolated, retrotranscribed to
cDNA and ligated into the library vector pJG4–5 at the EcoRI and XhoI sites by Express Geno-
mics (Baltimore, MD). This cDNA library contained 3.51 x 107 total cfu with an average insert
size of 1.4kb.
Yeast three-hybrid screens
The cDNA library was used to transform competent V784Y yeast using a library scale transfor-
mation as previously described (Clontech Matchmaker GAL4 Two-Hybrid System 3 & Librar-
ies User Manual and ref. [32]). The transformation mix was then plated on 50 x 15mm
dropout plates (SC +Glu-his-trp-ura). Transformants were collected, pooled, aliquotted and
stored at -80°C. The plates were spread with CID using sterile glass beads the day before the
start of the screen to give the final desired concentration. For each Y3H screen, one aliquot of
yeast transformed with the cDNA library (~1 x 1010 cells) was thawed and diluted 1:10 in SC
+Gal/Raff-his-trp-ura media and incubated with shaking at 30°C for 4 hr to induce the Gal1
promoter. The cell suspension was diluted in SC +Gal/Raff-his-trp-ura-leu to give an OD600 of
approximately 0.3 and plated using sterile glass beads onto dropout plates (SC +Gal/Raff-his-
trp-ura-leu +CID). As a negative control, library transformed yeast were also plated on one
equivalent dropout plate spread with DMSO. Plates were inverted and incubated 3–5 days at
30°C. The screen was terminated when growth appeared on the negative control plate.
Yeast Colony Hybridization
Radioactive probes were synthesized by PCR as previously described [33], using Thermopol
Buffer, Taq Polymerase (New England Biolabs, Ipswich MA) and 20μM each of dATP/dTTP/
dGTP supplemented with 3.3μM α32P-dCTP (3000Ci/mmol; MP Biomedicals, Santa Ana CA).
The primers used to amplify/label the probes were P9 and P10 for the TgCDPK1 probe and
P11 and P12 for the TgBRADIN probe (S1 Table). The TgCDPK1 labeled probe (1.2kb) covered
the 5’ end of the TgCDPK1 coding sequence. The TgBRADIN labeled probe (0.8kb) covered
the 3’ of the TgBRADIN-b coding sequence. The labeled probes were purified using a PCR pu-
rification kit (QIAGEN) to remove unincorporated dNTPs. The labeling efficiency was 2x107
cpm/μg DNA.
Yeast colonies from each hit in the Y3H screens were grown on dropout plates with the ap-
propriate selection at 30°C for 1–2 days and subjected to colony hybridization with the
TgCDPK1 and TgBRADIN probes. The protocol used for hybridization was adapted from a
previously described method [34]. Yeast colonies were lifted on Hybond N+ nylon membrane
(Amersham Biosciences, Pittsburgh PA) and the membrane incubated on filter paper soaked
with spheroblasting solution (1M sorbitol, 20mM EDTA, 10mM Tris-HCl, 14mM beta-mer-
captoethanol and 100U/ml Zymolyase 20T (Seikagaku Corporation, Tokyo, Japan)) overnight
at 37°C. The degree of cell wall breakage was assessed by visualization under the microscope.
The membrane was then incubated for 10 min in each of the following solutions (colony side
up on soaked sheets of filter paper): denaturing solution (1.5M NaCl, 0.5M NaOH); neutraliz-
ing solution (1.5M NaCl, 0.5M Tris-HCl pH 7.4); 0.5M Tris-HCl/6x sodium chloride/sodium
citrate solution (SSC); and 2xSSC. The membrane was air-dried between incubations. UV-
crosslinking of the DNA to the membrane was performed using a Stratalinker 1800 (Agilent
Technologies).
The membrane was pre-hybridized for at least 1 hr at 65°C in hybridization solution (1% w/v
BSA, 1mM EDTA, 0.5M NaHPO4 pH 7.2, 7% w/v SDS). The radioactive probe was boiled and
TgBRADIN/GRA24 Inhibits the Differentiation of T. gondii
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diluted to 0.5–1x106 cpm/ml in hybridization solution with 2mg of sonicated salmon sperm
DNA. The hybridization of the membrane with the probe was done in a sealed bag at 65°C over-
night. The membrane was washed three times with 250ml of low stringency wash buffer (0.5%
w/v BSA, 1mM EDTA, 40mMNaHPO4 pH 7.2, 5% w/v SDS) at 23°C and three times with high
stringency wash buffer (1mM EDTA, 40mMNaHPO4 pH 7.2, 1% w/v SDS) at 65°C. Mem-
branes were exposed on BioMaxMR film (Kodak, Rochester NY) at -80°C for 24–48 hr.
TgBRADIN targeting construct
Flanking sequences to generate the TgBRADIN targeting construct were amplified using prim-
ers P13 and P14 for the 5’ flanking region (608bp) and P15 and P16 for the 3’ flanking region
(687bp) (S1 Table). Flanks were amplified from RH tachyzoite genomic DNA (gDNA) ex-
tracted using DNAzol Reagent (Invitrogen) followed by ethanol precipitation. The PCR prod-
ucts were digested: with HindIII and KpnI (5’ flank) or BamHI and XbaI (3’ flank). Each
fragment was then ligated into the respective sites in pGRA1ble [35]. The resulting plasmid
(100μg) was digested with KpnI/XbaI and used for transfection of wild-type parasites (RH
Δku80 Δhxgprt; see S2 Table)
TgBRADIN isoform PCR amplification
PCR of tachyzoite cDNA to amplify the 3’ end of TgBRADIN isoforms was performed using
primers P7 and P8 for TgBRADIN-a and P17 and P18 for TgBRADIN-b (S1 Table).
T. gondii transfection and selection
Transfections were performed by electroporating 2 x 107 wild-type parasites (model BTX
ECM630 electroporator) resuspended in Cytomix Buffer (120mMKCl, 0.15mM CaCl2, 10mM
potassium phosphate pH 7.6, 25mMHEPES-KOH pH 7.6, 2mM EDTA, 5mMMgCl2) supple-
mented with 2mMATP and 5mM reduced glutathione. After transfection, enrichment of the
Δbradin parasites was done by two rounds of selection in the presence of 50μg/ml and 5μg/ml
phleomycin as described previously [35]. Individual clones were isolated in 96-well plates by di-
luting the population and seeding each well with an estimated three parasites per well. Homolo-
gous recombination events were evaluated by PCR on gDNA, extracted from parasites using
DNAzol reagent followed by ethanol precipitation. The PCRs used to evaluate the knockout are
shown in S1 Fig (primers P19 and P20 for PCR A, and P19 and P21 for PCR B, S1 Table).
Wild-type and Δbradin parasites were transfected with pUPRTKO plasmid digested with
BglII as previously reported [36] to generate the corresponding Δuprt and Δbradin Δuprt para-
site lines (S2 Table). Parasites resistant to 5μM 5’-fluorodeoyuridine (FUDR) were obtained
after two rounds of selection and clones isolated as described above. Recombination was con-
firmed with gDNA extracted from individual clones using a previously described PCR ap-
proach (primers P22 and P23 [36] for PCR C, S1 Table).
Southern blot analysis of Δbradin parasites
Genomic DNA was extracted from wild-type and Δbradin parasites as above. 7.5ug of DNA
was digested with SspI and RNAseA overnight. The digested DNA was electrophoresed in a
0.7% w/v agarose gel and transferred onto Hybond N+ nylon membrane by capillary transfer
in alkaline solution [37].
Biotinylated probes were synthesized by PCR using Thermopol Buffer with Taq polymerase
(New England Biolabs), 20μM each of dATP/dCTP/dGTP supplemented with a 50/50% mix of
dTTP/biotinylated-dUTP (20μM final concentration) and gDNA (for probe 1) or plasmid
TgBRADIN/GRA24 Inhibits the Differentiation of T. gondii
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pGRA1ble (for probe 2) as template. The primers used to amplify/label probe 1 were P19 and
P20, which generate a 0.9kb fragment, and P24 and P25 for probe 2, which amplify the bleR
coding sequence yielding a 0.35kb product (S1 Table). The labeled probes were purified using a
PCR purification kit (QIAGEN).
The membrane was pre-hybridized for at least 1 hr at 64°C in hybridization solution (see
above). Biotinylated probe 2 was boiled and diluted to 300 ng/ml in hybridization solution
with 2mg of sonicated salmon sperm DNA. Hybridization of the membrane with probe was
done in a sealed bag at 64°C overnight. The membrane was washed 3 times with 250ml of low
stringency wash buffer (see above) at 21°C and three times with high stringency wash buffer
(see above) at 55°C. The membrane was then developed using the Pierce Chemiluminescent
Nucleic Acid detection kit following manufacturer’s instructions (Thermo Scientific, Rockford
IL). Membrane was exposed on film (Bioworld, Dublin OH) for 5 sec-30 min. The membrane
was stripped by 30 min incubation in 0.4M NaOH at 45°C followed by 10 min in moderate
stripping solution (200mM Tris-HCl pH 7.0, 0.1x SSC and 0.1% w/v SDS) at 21°C. The same
membrane was re-hybridized with probe 1 as described above but using a hybridization tem-
perature of 66°C.
T. gondii replication assay
Confluent HFF monolayers grown on coverslips in 12- well plates were infected with 5x104
parasites per well. Coverslips were fixed 12, 24, or 36 hr post-infection and processed for
immunofluorescence as described above, using mouse anti-IMC1 MAb 45.36 and goat anti-
mouse IgG conjugated to Alexa 488. All vacuoles in 100 randomly selected fields were scored
and classified according to the number of parasites per vacuole.
T. gondii invasion assay
1.5x105 parasites were allowed to invade confluent HFF monolayers grown in each well of an
8-well chambered coverglass (Thermo Scientific) for 1 hr at 37°C. Loosely attached extracellu-
lar parasites were washed away with PBS and cells were fixed and processed for immunofluo-
rescence as described above, using mouse anti-SAG1 IgG (Argene, Sherley NY) diluted 1:1000,
followed by goat anti-mouse IgG conjugated to Alexa 546. After permeabilization with 0.25%
v/v Triton X-100, samples were incubated sequentially with the same primary antibody fol-
lowed by goat anti-mouse IgG conjugated to Alexa 488. Samples were imaged at 20X on a
Nikon Eclipse TE300 epifluorescence microscope. All intracellular parasites in the well were
counted and the continuity of the HFF cell monolayer across the entire well was confirmed by
phase microscopy.
Statistical analysis
Growth, differentiation, replication and invasion assays were analyzed using Student’s t-test or
two-way ANOVA with GraphPad Prism5 (GraphPad Software, La Jollla CA).
Results
Compound 2 enhances T. gondii differentiation
We first tested whether Compound 2 could enhance parasite differentiation. For these experi-
ments, we used a type I strain of T. gondii that shows a preference for homologous recombination
because it lacks a key gene involved in non-homologous end joining (KU80) [38,39]. Because
type I strains show low differentiation levels we also disrupted the TgUPRT gene (S1 Fig) to inter-
fere with the pyrimidine salvage pathway, thereby rendering these parasites more susceptible to
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differentiation under CO2 starvation conditions [36,40]. Parasites were allowed to invade a con-
fluent host cell monolayer for 2 hr prior to addition of Compound 2 (or DMSO as vehicle) since
Compound 2 inhibits parasite invasion of the host cell [24]. The percentage of parasite vacuoles
that converted to cysts after a further 72 hr incubation under low CO2 conditions was assessed
using fluorescently-conjugated Dolichos biflorus lectin (DL) which labels the sugars in the cyst
wall [41] (Fig. 1B). As shown in Fig. 1C, Compound 2 treatment increased differentiation in both
wild-type (non-disrupted TgUPRT) and Δuprt strains, compared to the vehicle-treated controls.
A similar result was obtained with type II parasites (Prugniaud strain), despite these parasites
showing higher basal levels of differentiation (S2 Fig).
Compound 2 target profile in T. gondii
As a first step in determining how Compound 2 enhances differentiation, we used yeast
three-hybrid (Y3H) analysis [32,42–46] to examine the target profile of Compound 2 in T.
gondii. Y3H is a modified version of yeast two-hybrid analysis in which the bait and prey/
target proteins are brought together by a bridging molecule containing the small molecule of
interest, thereby allowing identification of small molecule—protein interactions (Fig. 2A).
The bivalent bridging molecule is referred to as a Chemical Inducer of Dimerization (CID).
The bait and prey proteins are fused to the two functional domains of a transcription factor,
so that the formation of a ternary complex consisting of bait, prey and CID leads to the acti-
vation of one or more reporter genes. Using this methodology, a cDNA library encoding par-
asite proteins can be screened for potential targets whose interaction with the CID leads to
reporter activation.
The Compound 2-derived CID (MTX-Cmpd2.1) was prepared in three key steps (Fig. 2B).
First, a published structure-activity relationship (SAR) study for Compound 2 suggested that
the primary amino group was a suitable point for attachment of a linker, as substitution at this
position resulted in retention of the compound’s inhibitory activity against its previously de-
scribed targets [26]. Sulfone 2, prepared in seven steps from 1 (see Scheme I in S1 Methods)
was therefore converted to 3 through reaction with an N-Boc protected PEG linker [45] fol-
lowed by subsequent N-Boc deprotection (Fig. 2B and Scheme II in S1 Methods). Second, the
synthesis of tbutyl methotrexate 5 was achieved in good yield by in situ conversion of 4 to the
corresponding bromide followed by reaction with 4-(methylamino)benzoic acid and coupling
to a derivative of L-glutamic acid partially protected as the mono-tert-butyl ester (Fig. 2B and
Scheme III in S1 Methods) [47]. Finally, TPTU-mediated coupling of 3 with 5 provided the
tbutyl CID S13. Subsequent ester hydrolysis using TFA in the presence of thioanisole gave
MTX-Cmpd2.1.
We used MTX-Cmpd2.1 to screen a T. gondii tachyzoite oligo(dT)-primed cDNA library
and obtained 172 hits, i.e., yeast colonies that reproducibly grew on selective media differential-
ly in the presence of CID (Table 1). Recovery and sequencing of the yeast plasmids revealed
that the hits obtained did not encode any of the kinases previously described as targets of Com-
pound 2 (TgPKG, TgCDPK1 and TgCK1α) [24]. Instead, a high percentage of the hits (81%)
corresponded to TgME49_230180, which we named TgBRADIN (BRAdyzoite Differentiation
INhibitor) for reasons discussed below. Similar results were obtained in a second independent
screen in which the hits were analyzed by colony hybridization for the presence of TgBRADIN
(discussed further below).
Summary of the hits obtained in the screen with 5μMMTX-Cmpd2.1. The percentages indi-
cated were obtained by sequence analysis of plasmids isolated from 36 of the colonies that
showed MTX-Cmpd2.1-dependent reporter activation.
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Interaction between MTX-Cmpd2.1 and its predicted targets in the Y3H
system
The lack of interaction between Compound 2 and its predicted kinase targets in the Y3H screen
was unexpected. PCR analysis demonstrated that sequences encoding full-length TgCK1α
and the predicted compound-binding domain of TgPKG are present in the cDNA library, where-
as the predicted compound-binding site in TgCDPK1 is not (data not shown). To test whether
these three kinases are capable of interacting with MTX-Cmpd2.1 in a Y3H format, we cloned
the entire coding sequence of each in frame with the B42 activation domain and tested it for
Fig 2. Y3H and CID synthesis. A. Schematic of the Y3H system showing the ternary complex between the CID and the two fusion proteins containing the
activation and DNA-binding domains of the transcription factor (AD and DBD, respectively). The CID consists of: methotrexate (green cross), which binds to
the DHFR-DBD fusion; a flexible linker unit (red); and the small molecule of interest (blue star), which binds to the target protein-AD fusion. B. Synthetic route
to MTX-Cmpd2.1 (i) Compound 2-PEG linker fragment 3; (ii) tButyl Methotrexate 5 and (iii) Peptide coupling and tbutyl deprotection to MTX-Cmpd2.1. For
reagents and conditions, see S1 Methods.
doi:10.1371/journal.pone.0120331.g002
Table 1. Screen results with MTX-Cmpd2.1.
Number of hits that showed MTX-Cmpd2.1-dependent reporter activation 172
% Positive hits corresponding to TgME49_030180 (TgBRADIN) 81
% Positive hits corresponding to TgCK1α 0
% Positive hits corresponding to TgPKG 0
% Positive hits corresponding to TgCDPK1 0
doi:10.1371/journal.pone.0120331.t001
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interaction with the CID. Activation of the LacZ and LEU2 reporter genes was evaluated in liquid
growth and β-galactosidase assays. Of the three kinases, only TgCDPK1 interacted with MTX-
Cmpd2.1 in the Y3H system (Fig. 3A and B; see also [46]). Reporter activation with TgCDPK1
was dose dependent for MTX-Cmpd2.1 concentrations in the micromolar range (Fig. 3C and D;
[46]). Another methotrexate-containing CID (MTX-118793.1 [45]) did not activate any reporter
genes, demonstrating that the interaction between TgCDPK1 andMTX-Cmpd2.1 is CID-specific
(Fig. 3C and D).
While TgCDPK1 is capable of binding the Compound 2 portion of MTX-Cmpd2.1 and
turning on the LEU2 and LacZ reporter genes, it is not detectable within our cDNA library.
This observation provided an opportunity to assess the sensitivity of our Y3H screening meth-
ods with respect to target copy number. We added TgCDPK1-expressing yeast to the total
yeast cDNA library in ratios ranging from 1:1,000 to 1:1,000,000. The pools were screened with
MTX-Cmpd2.1 and the hits from the screens were analyzed by yeast colony hybridization to
determine whether they contained TgCDPK1 or TgBRADIN (S3 Fig). The data show that for a
target compound pair such as TgCDPK1-Compound 2 (IC50 = 0.7nM [24]), the target can be
detected if it is represented in the library at a frequency of between 1:100,000 and 1:1,000,000.
It therefore seems likely that TgCDPK1 did not appear as a hit in the initial Y3H screen due to
under-representation in our cDNA library; the reason for the lack of interaction between
Fig 3. Interaction betweenMTX-Cmpd2.1 and the predicted targets of Compound 2 in the Y3H system. A. Y3H interaction between TgCK1α, TgPKG,
TgCDPK1 and various concentrations of MTX-Cmpd2.1; representative images of the in-plate growth assay at 72 hr are shown. Yeast transformed with an
empty pJG4–5 vector containing a stop codon immediately after the cloning site was used as a negative control. B. 72 hr liquid growth assays with either
10μMMTX-Cmpd2.1 or an equivalent amount of DMSO (mean ± SD, n = 3). C and D. Dose response analysis and specificity of the Y3H interaction of
TgCDPK1 with MTX-Cmpd2.1 as measured by either (C) β-Galactosidase activity or (D) LEU2-mediated liquid growth in the presence of MTX-Cmpd2.1,
MTX-118793.1 (an unrelated CID) or DMSO (mean ± SD, n 3).
doi:10.1371/journal.pone.0120331.g003
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MTX-Cmpd2.1 and its other two predicted kinase targets will be the subject of
future investigation.
TgBRADIN and its interaction with MTX-Cmpd2.1
TgBRADIN is a T. gondii-specific gene that has no identifiable orthologs, including in other
apicomplexan parasites. The same gene was recently shown to encode a protein secreted into
the host cell cytosol, possibly from a subset of the dense granules ([48]; see Discussion below).
The protein contains a predicted N-terminal signal peptide, a second internal hydrophobic
stretch and a bipartite nuclear localization signal that is likely responsible for trafficking of the
secreted protein to the host cell nucleus (Fig. 4A; [48]).
The sequenced hits from the Y3H screen showed varying degrees of coverage of the TgBRA-
DIN coding sequence. Since the cDNA library was oligo(dT) primed, the coverage of TgBRA-
DIN included in all cases the 3’ end of the mRNA. We tested four hits from the screen with
different degrees of coverage of the coding sequence (#172, 4, 34, 154; Fig. 4A) for their ability
Fig 4. Y3H interaction between MTX-Cmpd2.1 and TgBRADIN. A. TgBRADIN (TgME49_230180) encodes a predicted N-terminal signal peptide (SP;
yellow box), a central stretch of hydrophobic amino acids (HR; red box) and a predicted bipartite nuclear localization sequence (NLS; green box). Hits #172, 4,
34 and 154 were identified in the Y3H screen (starting at residues H173, T304, P324 and V398 and, respectively); coverage of the coding sequence of each is
indicated by the black bars, and the corresponding activation of the LEU2 reporter by 5μMMTX-Cmpd2.1 is shown on the right (mean ± SD, n = 3). The data
were compared by paired Student’s t-test (*p< 0.015, **p< 0.01, ns = not significant,). B. Competition growth assay performed using hit #4 andMTX-
Cmpd2.1 in the presence of various concentrations of Compound 2 as competitor. The first two columns correspond to growth in non-selective media and the
following four correspond to the growth in media lacking leucine (mean ± SD, n = 3). The data were compared by one way ANOVA (*p< 0.05, **p< 0.01).
doi:10.1371/journal.pone.0120331.g004
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to interact with MTX-Cmpd2.1 in a LEU2 reporter growth assay. As shown in Fig. 4A, the level
of reporter gene activation correlates with the coverage of the open reading frame, although hit
#172, which includes the internal hydrophobic stretch, shows very little reporter activation.
The hydrophobic stretch may inhibit the Y3H interaction between TgBRADIN and MTX-
Cmpd2.1 either because it disrupts the folding of the protein or interferes with trafficking into
the yeast nucleus. These data demonstrate that the N-terminal half of TgBRADIN is dispensi-
ble for its Y3H interaction with MTX-Cmpd2.1.
Fig. 4B shows that the interaction between MTX-Cmpd2.1 and TgBRADIN can be compet-
ed by an excess of Compound 2. This observation, together with the lack of interaction of
MTX-118793.1 with TgBRADIN (Fig. 3C and D), confirms that the Y3H interaction of
TgBRADIN and MTX-Cmpd2.1 involves the Compound 2 moiety, rather than some other
part of the CID.
TgBRADIN is alternatively spliced and its Y3H interaction with
Compound 2 is isoform-specific
During attempts to amplify the TgBRADIN gene from cDNA, we discovered that multiple dis-
tinct mRNA transcripts are generated from the TgBRADIN locus and that these transcripts are
created by alternative splicing. We focused on the portions of the transcripts that encode the
C-terminal half of TgBRADIN (exons 3–8, see S1 Fig for gene schematic), the region required
for a positive Y3H interaction with the Compound 2-based CID. We PCR amplified this por-
tion of the predicted gene from cDNA using two sets of primers (Fig. 5A) and sequenced sever-
al isoforms. Two isoforms were chosen that encode proteins with different C-terminal ends,
TgBRADIN-a and TgBRADIN-b. TgBRADIN-a, which encodes a fragment that extends from
the central hydrophobic stretch to the C-terminus, was cloned in frame with the activation do-
main in the target Y3H vector. Hit #4 from the Y3H screen (Fig. 4A) was used as a representa-
tive TgBRADIN-b sequence. Each was tested for its ability to interact with MTX-Cmpd2.1 by
Y3H. The TgBRADIN-b isoform showed much more sensitive compound-dependent tran-
scription of the LEU2 reporter gene than TgBRADIN-a (Fig. 5B and C). In agreement with this
result, none of the hits sequenced in the original Y3H screen with MTX-Cmpd2.1 contained
the TgBRADIN-a splicing pattern at the 3’ end. These results show that different naturally-oc-
curring isoforms of TgBRADIN interact differentially with Compound 2 in the Y3H format.
We also explored whether reporter activation with TgBRADIN-b was specific for Com-
pound 2 or if it could also occur with the related small molecule, Compound 1. As shown in
Fig. 5C, while TgBRADIN-b shows a strong Y3H interaction with MTX-Cmpd2.1, it shows no
detectable interaction with a CID based on Compound 1 (MTX-Cmpd1.1).
Parasites lacking TgBRADIN show a differentiation phenotype
The observation that Compound 2 both enhances bradyzoite differentiation and interacts with
TgBRADIN in Y3H assays led us to hypothesize that TgBRADIN functions in differentiation.
To test this hypothesis, we deleted the TgBRADIN gene in the wild-type strain (S2 Table). Di-
agnostic PCRs confirmed that the TgBRADIN locus was disrupted and Southern blotting dem-
onstrated that the deletion cassette integrated only once in the genome, at the TgBRADIN
locus (S1 Fig). We then disrupted the TgUPRT gene in this background, as described above, in
order to test the ability of the TgBRADIN knockout parasites to differentiate under low CO2
conditions. The ΔbradinΔuprt parasites showed a significant enhancement of differentiation
upon CO2 starvation compared to parasites expressing TgBRADIN, as assayed either by bind-
ing of Dolichos biflorus lectin or by expression of the bradyzoite-specific marker BAG1
(Fig. 6A).
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When parasites are induced to differentiate into bradyzoites their cell cycle slows and they
enter into a lateS/G2 phase, suggesting a connection between cell cycle regulation and initiation
of the differentiation program [49,50]. A mutant parasite that differentiates better than wild
type might therefore replicate more slowly. We tested this hypothesis by evaluating the replica-
tion rate of wild-type and Δbradin (TgUPRT+) parasites under normal tachyzoite growth con-
ditions, and saw no differences in the number of parasites per vacuole at any time point during
the assay (S4 Fig). Generation of the Δbradin parasite strain also allowed us to test whether
TgBRADIN plays a role in invasion. The Δbradin parasites showed no defect in invasion com-
pared to wild type (S5 Fig) suggesting that Compound 2’s effect on differentiation and its previ-
ously reported effect on invasion [24] likely occur through different mechanisms.
If TgBRADIN plays a role in Compound 2’s ability to enhance differentiation, then the
Δbradin parasites should be less sensitive to Compound 2 treatment. To test this hypothesis,
we treated wild-type and Δbradin parasites with varying concentrations of Compound 2 and
assessed their ability to differentiate under CO2 starvation conditions. We used TgUPRT
+
Fig 5. The TgBRADIN Y3H interaction with Compound 2 is isoform-specific. A. Schematic showing exons 3–8 from two of the TgBRADIN isoforms
generated by alternative splicing of TgBRADIN (see S1A Fig for schematic of the entire gene). Two PCRs are shown on the right using primers P7 and P8 for
TgBRADIN-a and P17 and P18 for TgBRADIN-b (arrows). The bands marked with the asterisks correspond to the splicing pattern of either TgBRADIN-a
(blue) or TgBRADIN-b (red, hit #4 from the Y3H screen) as determined by sequencing of the PCR products. B. The C-terminal half of the coding sequence
corresponding to either TgBRADIN-a or TgBRADIN-bwas tested in an in-plate growth assay (5 days at 30°C) with MTX-Cmpd2.1 at the concentrations
shown.C. The same yeast expressing TgBRADIN-a or TgBRADIN-bwere used in a liquid growth assay with MTX-Cmpd2.1 or MTX-Cmpd1.1 (a Compound
1-derived CID) (mean ± SD, n = 3).
doi:10.1371/journal.pone.0120331.g005
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strains in this case to maximize the difference between treatments since the Δuprt strains show
a higher basal level of differentiation (Fig. 1C). At Compound 2 concentrations of 1.5μM or
higher, there was no difference in differentiation between wild-type and Δbradin parasites, but
when the concentration of Compound 2 was decreased to 0.5μM the Δbradin parasites showed
half the induction of wild type (Fig. 6B). These data demonstrate that a portion of the differen-
tiation enhancement caused by Compound 2 is indeed mediated by TgBRADIN, and suggest
that other as yet unidentified target(s) of Compound 2 also contribute to the process.
Fig 6. Parasites lacking TgBRADIN show increased differentiation and reduced sensitivity to
Compound 2. A. Differentiation of Δuprt and Δbradin Δuprt strains under CO2 starvation was measured
either by staining with Dolichos biflorus lectin (DL; mean ± SD, n = 21) or by immunofluorescence with anti-
BAG1 (BAG1; mean ± SD, n = 3). The data were compared by paired Student’s t-test (*p< 0.05, ****p<
0.0001). B. Differentiation assay comparing parental wild-type and Δbradin strains treated with either
Compound 2 or an equivalent volume of DMSO for 72 hr under CO2 starvation conditions (mean ± SD, n 4).
The data were compared by two-way ANOVA (***p< 0.001, ns = not significant).
doi:10.1371/journal.pone.0120331.g006
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Discussion
The mechanisms and pathways underlying T. gondii differentiation remain poorly understood,
despite numerous studies aimed at identifying differentiation effector and regulator genes
[8–10,12–16,51]. An important recent advance was the identification of T. gondii transcription
factors containing AP2 DNA binding domains and the demonstration that some of these tran-
scription factors regulate the tachyzoite-to-bradyzoite/tissue cyst transition [17,18]. For exam-
ple, overexpression of AP2IX-9 represses bradyzoite induction, and disruption of AP2IX-9
increases cyst formation [17]. AP2IX-9 therefore functions as a repressor of tachyzoite-to-bra-
dyzoite differentiation, and likely acts by binding to cis-regulatory DNA elements that control
stage-specific gene expression [17].
TgBRADIN and the serine protease inhibitor, TgPI [51], are two other tachyzoite proteins
that appear to function as negative regulators of T. gondii differentiation. As with TgBRADIN,
parasites in which TgPI is disrupted show an increased rate of in vitro differentiation, and the
expression data available in ToxoDB [52] show that transcription of both TgPI and TgBRADIN
decreases shortly after tachyzoites are induced to differentiate into bradyzoites. The expression
of TgBRADIN is in fact highest in the oocyst stage, intermediate in tachyzoites and lowest in
bradyzoites. Oocysts are produced within the intestine of the cat and must differentiate into
sporozoites prior to infecting a new host; it will therefore be of interest to determine whether
TgBRADIN plays any role in regulating the oocyst-to-sporozoite transition.
While this manuscript was under review, another group independently published a study on
TgBRADIN (which they named GRA24 [48]), and their results suggest an intriguing potential
mechanism by which TgBRADIN/GRA24 and Compound 2 might affect differentiation. In
brief, these authors showed that TgBRADIN/GRA24 is secreted by the intracellular parasite into
the host cell cytosol, where it associates directly with host p38αMAP kinase (p38αMAPK).
Binding of TgBRADIN/GRA24 to p38αMAPK results in an unusually persistent autopho-
sphorylation/activation of the kinase and its translocation to the host cell nucleus. Within the
nucleus, the activated kinase upregulates several important host cell transcription factors and al-
ters the expression of a number of genes, including those that control proinflammatory cytokine
and chemokine production [48]. It is possible that TgBRADIN/GRA24 regulates parasite differ-
entiation through similar p38αMAPK-mediated changes in host cell gene expression; further
studies will be required to test this hypothesis and to identify the specific genes involved. There
is precedent for a host cell gene mediating the differentiation-enhancing activity of a small mole-
cule: the ability of Compound 1 to enhance bradyzoite formation depends, in part, on the host
cell cycle regulator CDA-1 [22].
How would Compound 2 enhance differentiation in this model? Because Compound 2 is an
ATP analog and well-established kinase inhibitor [23,24], we hypothesize that it binds to p38α
MAPK rather than directly to TgBRADIN/GRA24 (which has no apparent ATP-binding
motif). This would be consistent with our inability to show direct binding of Compound 2 to
recombinantly expressed TgBRADIN/GRA24 by a variety of biochemical techniques (AVO
and GEW, unpublished data). However, if Compound 2 binds to p38αMAPK and not TgBRA-
DIN/GRA24, why did we so consistently recover TgBRADIN/GRA24 in our Y3H screens with
MTX-Cmpd2.1? We propose that the TgBRADIN/GRA24-activation domain fusions in our
cDNA library bind to yeast p38αMAPK (also known as HOG1), which in turn binds to the
Compound 2 portion of the CID, ultimately forming a (DNA binding domain-DHFR)—
(MTX-Cmpd2.1)—(p38αMAPK)—(TgBRADIN/GRA24-activation domain) quaternary
complex that activates reporter gene expression (see schematic, S6 Fig). This model is consis-
tent with our observation that the C-terminal half of TgBRADIN/GRA24, i.e., the portion that
contains the KIM/D motifs required for binding to p38αMAPK [48], is sufficient for a positive
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Y3H interaction with MTX-Cmpd2.1 (Fig. 4A). While the actual formation of such a quaterna-
ry complex will require biochemical confirmation, these results raise the possibility that Y3H
can be used to identify both direct and indirect binding partners of small molecules of interest.
At the same time, they sound a cautionary note about how Y3H results should be interpreted
and hits validated.
One intriguing feature of the TgBRADIN/GRA24 gene is the large number of splice variants
expressed, likely beyond the two isoforms previously described [48]). It is, in fact, among the
most highly alternatively spliced genes in the transcriptome (B. Thompson and M. Matrajt,
personal communication). This suggests either high functional versatility or complex regula-
tion of TgBRADIN/GRA24 expression. TgPI also undergoes alternative splicing, into two iso-
forms, neither of which alone can fully reverse the enhanced differentiation observed in
parasites with the TgPI gene disrupted. Alternative splicing as a regulatory mechanism has
been understudied in T. gondii. Recent analyses suggest that a large number of T. gondii tran-
scripts are in fact alternatively spliced ([53] and http://www.toxodb.org), introducing another
level of variability and dynamics to the regulation of gene expression in T. gondii and expand-
ing the total number of protein isoforms the parasite is capable of producing. A complete cata-
log of all the biologically relevant splicing isoforms generated by TgBRADIN/GRA24, their
stage specificities, and their biological functions will be the subject of future investigation.
The TgBRADIN/GRA24 knockout parasites were only partially resistant to the effects of
Compound 2, suggesting either that compensatory parasite mutations developed during genera-
tion or growth of the knockout or, more likely, that other direct or indirect targets of Compound
2 are also involved. TgPKG, TgCDPK1 and/or TgCK1α, all known targets of Compound 2 [24],
might have an undiscovered role in differentiation, synergizing with TgBRADIN/GRA24 during
this process. Given the similarities between Compound 2 and Compound 1, the unidentified
target of Compound 1 in the host cell that mediates its differentiation-enhancing activity
through CDA-1 [22] represents another potential target of Compound 2 that could synergize
with TgBRADIN/GRA24 to produce the differentiation phenotype observed. A systematic analy-
sis of these potential targets and additional Y3H screens with alternative Compound 2-based
CIDs and different cDNA libraries (including host cell cDNA libraries) will ultimately help to
establish the complete target profile of Compound 2 in T. gondii-infected cells.
Differentiation is essential for T. gondii’s successful transmission between intermediate
hosts. Most acute infections in humans are acquired by ingestion of undercooked meat of ani-
mals containing tissue cysts or oocyst-contaminated food and water [54]. The infection devel-
ops into the chronic phase, which is generally not a threat to human health. However, if the
host is immunocompromised, the recrudescence of a chronic infection, during which latent
bradyzoites differentiate to tachyzoites, can be life-threatening [2,3]. As a consequence, chemo-
therapeutics that either eliminate tissue cysts or prevent their formation would be clinically
useful. While there are currently no drugs available for this purpose, our results and those of
others [7,13,22,55,56] demonstrate clearly that small molecules are capable of affecting the
pathways that regulate differentiation. High-throughput small molecule screening for com-
pounds that affect differentiation may therefore provide a new approach to discovering drugs
that block cyst formation or reactivation, and Y3H will provide a complementary means to de-
termine the target profile of these bioactive compounds.
Supporting Information
S1 Fig. Generation of the Δbradin strain. A. Schematic showing the strategy used to obtain
the Δbradin parasite line. Empty boxes represent predicted exons (numbered) in the TgBRA-
DIN locus. Hatched areas flanking the TgBRADIN gene were used for homologous
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recombination of the phleomycin resistance cassette (bleR) into the locus. Both the parental
wild-type and Δbradin parasite lines (parental clones 1 and 2 and Δbradin clones 3 and 4) were
transfected to disrupt the TgURPT locus. S: SspI restriction sites. B. PCRs were performed on
gDNA of isolated parasite clones, amplifying the regions indicated in panel A. Expected ampli-
con size of PCR A: 0.9kb and PCR B: 0.8kb. PCR C, performed as described previously [36],
was used to confirm the disruption of the TgUPRT locus (Δuprt: 0.5kb; TgUPRT: 1.5kb). C.
Ethidium bromide stained gel of SspI digested genomic DNA from wild-type (clone 1) and
Δbradin (clone 3) parasites. Southern blot showing the hybridization of probes 1 and 2 on the
digested DNA; the expected 2.1 and 2.5kb restriction fragments (see panel A) are indicated by
the orange and green arrowheads, respectively.
(TIF)
S2 Fig. Compound 2 enhances differentiation in Type II parasites. Percentage of Dolichos
lectin-positive vacuoles (DL+) in samples treated with either DMSO or Compound 2 (3μM)
for 72 hr under CO2 starvation conditions (mean ± SD, n = 3). The data were compared by
paired Student’s t-test (p< 0.05).
(TIF)
S3 Fig. Determining the sensitivity of TgCDPK1 detection in the Y3H screening format
with MTX-Cmpd2.1. A. A series of screens were undertaken using the unmodified cDNA li-
brary and the same library spiked with varying ratios of yeast carrying the plasmid pJG4–5 con-
taining the TgCDPK1 coding sequence. Forty colonies from each screen were analyzed by
colony hybridization to determine the number that carried a plasmid encoding either
TgCDPK1 or TgBRADIN. The black dots correspond to the hybridization signal using a probe
directed against either TgCDPK1 or TgBRADIN, as indicated on the left. B. Graphical represen-
tation of the results from panel A.
(TIF)
S4 Fig. Parasites lacking TgBRADIN show no replication defect. Replication assay compar-
ing wild-type and Δbradin parasites. Number of parasites per vacuole was determined at 12, 24
and 36 hrs post-infection. 100 fields were counted at each timepoint, with two replicates per ex-
periment (mean ± SD shown, n = 3). No significant differences were found by Student’s t-test
at any time point.
(TIF)
S5 Fig. Parasites lacking TgBRADIN show no invasion defect. Invasion assay comparing
wild-type and Δbradin parasites (mean ± SD, n = 2). No significant differences were found be-
tween the strains by Student’s t-test.
(TIF)
S6 Fig. Schematic of a hypothetical quaternary complex between DHFR, MTX-Cmpd2.1,
yeast p38αMAPK and TgBRADIN/GRA24 that supports Y3H reporter gene activation.
Yeast p38αMAPK (orange) is predicted bind both to the Compound 2 portion of MTX-
Cmpd2.1 (blue) and to the C-terminal KIM/D motifs [48] of the TgBRADIN/GRA24-AD fu-
sion (red). Simultaneous binding of the MTX portion of the CID (green) to the DHFR-DBD fu-
sion (purple), reconstitutes the transcription factor and activates the reporter gene. AD =
Activation domain, DBD = DNA binding domain.
(TIF)
S1 Methods. Supplementary Chemical Synthesis Methods.
(DOCX)
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S1 Table. Primers used in this study.
(DOC)
S2 Table. Toxoplasma gondii strains used in this study.
(DOC)
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